(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
High-Suggested Broilers For Your Homes - 2The last penny was pressed by the U.S. Mint in Philadelphia today. Could the nickel and dime be next?
- 35 Indoor Plants That Further develop Air Quality
- 4Study finds humans were making fire 400,000 years ago, far earlier than once thought
- 5Baikonur launch pad damaged after Russian Soyuz launch to International Space Station
- Germany unveils rescue plan for struggling chemical sector
- A Gastronomic Experience in Healthy Enjoyments: A Survey of \Nutritious and Tasty\ Solid Cooking Recipe Book
- Watch Rocket Lab launch Japanese technology-demonstrating satellite to orbit tonight
- Manual for Individual accounting Rudiments for Fledglings
- The Land Rover Freelander Is Back—But It’s No Longer a Land Rover
- 6 Novice Cameras for 2024: Ideal for New Picture takers
- Italy fertility rate fell to new low of 1.14 in 2025
- Commonsense Ways to work on Your Funds with a Restricted Pay
- Netflix's 'Lord of the Flies' show blends 'Adolescence' and 'Yellowjackets'
